FindTrial
Sign In

Glycopyrronium

DRUG9 trials

Sponsors

Novartis Pharmaceuticals, GlaxoSmithKline, University of Saskatchewan, Centre Hospitalier Universitaire de Besancon, The Second Affiliated Hospital of Chongqing Medical University

Conditions

AsthmaCOPDChronic Obstructive Pulmonary DiseasePostoperative Nausea and VomitingPulmonary Disease, Chronic ObstructiveSialorrhea and droolingSubjects Undergoing Flexible Bronchoscopy

Phase 2

The effect of INhaled Glycopyrronium bromide on Excessive Sialorrhea and Drooling in Parkinson disease: a dose finding study
Active, not recruitingNL-OMON45524
Medisch Spectrum TwenteSialorrhea and drooling
Start: 2017-05-01Target: 10Updated: 2024-02-28
A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy
Not yet recruitingNCT06376942
Post Graduate Institute of Medical Education and Research, ChandigarhSubjects Undergoing Flexible Bronchoscopy
Start: 2024-04-24End: 2025-06-15Target: 1050Updated: 2024-04-22

Phase 4

Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD
CompletedNCT01959516
Novartis PharmaceuticalsCOPD
Start: 2014-02-28End: 2014-10-31Updated: 2016-04-15
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
CompletedNCT01985334
Novartis PharmaceuticalsCOPD
Start: 2014-02-14End: 2016-04-29Updated: 2019-03-19
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02236611
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2014-09-26End: 2015-06-02Updated: 2018-05-02
Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge
CompletedNCT02622243
University of SaskatchewanAsthma
Start: 2015-11-30End: 2016-03-31Updated: 2016-04-20
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02872090
Centre Hospitalier Universitaire de BesanconChronic Obstructive Pulmonary Disease
Start: 2016-03-31End: 2021-06-01Updated: 2021-08-03
Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve
CompletedNCT02953041
University of SaskatchewanAsthma
Start: 2016-10-31End: 2017-01-09Updated: 2017-06-14
Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron
NCT05265507
The Second Affiliated Hospital of Chongqing Medical UniversityPostoperative Nausea and Vomiting
Start: 2022-03-21End: 2023-05-30Target: 480Updated: 2023-02-24

Related Papers

Effects of long-acting bronchodilators on cardiac autonomic control in COPD.
2022-10-172 citations
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.
2018-05-102 citations
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
2018-04-1613 citations
The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study.
2017-08-0212 citations
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
Respiratory Research2017-07-1854 citations
Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics.
2016-07-3015 citations
A randomised, open-label study of umeclidinium<i>versus</i>glycopyrronium in patients with COPD
ERJ Open Research2016-04-0113 citations